Product News

Results presented at EADV by LEO Pharma show delgocitinib met primary and secondary end points in Phase 2b dose-finding study in mild-to-severe chronic hand eczema and reinforce the safety profile of investigational medicine tralokinumab in atopic dermatitis

Product News

Phase 2b dose-finding study showed that delgocitinib cream demonstrated a statistically significant dose-response relationship compared with vehicle in adults with

Read more